Real-World Evidence 1| COSELA®(trilaciclib)

Reduced rates of anemia and red blood cell transfusions with COSELA in a real-world study¹

Fewer red blood cell-related events from chemotherapy in patients receiving COSELA in a real-world study, including¹:

Grade 3/4 anemia (secondary endpoint)
Red blood cell transfusions (secondary endpoint)

COSELA administration can cause injection-site reactions, including phlebitis and thrombophlebitis

^a

Of the 62 patients identified who received etoposide/ carboplatin/atezolizumab + COSELA, 34 met the inclusion criteria for review. Inconsistent trilaciclib utilization from cycle 2 and onward was the most common reason for exclusion (n=11). Likewise, 44 patients in the etoposide/carboplatin/atezolizumab cohort were included for review from an initial list of 65 patients. Lost to follow-up (n=7) and carboplatin area under the curve <3.5 with cycle 1 (n=6) were the most common reasons for exclusion.¹

^*

Indicates statistical significance.

Real-world evidence is observational and may be subject to limitations, including lack of randomization.

< Previous Real-World Evidence: Platelets
Learn more >

Reduced rates of anemia and red blood cell transfusions with COSELA in a real-world study¹

Real-world evidence is observational and may be subject to limitations, including lack of randomization.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

This information is not comprehensive. Please see the Full Prescribing Information.

Reduced rates of anemia and red blood cell transfusions with COSELA in a real-world study1

Real-world evidence is observational and may be subject to limitations, including lack of randomization.

This site is intended for US healthcare professionals only.

You Are About to Leave This Site

Reduced rates of anemia and red blood cell transfusions with COSELA in a real-world study¹